Analysis Group Announces Consultant Promotions - 2018

Date:November 12, 2018
Contact:Eric Seymour
617-425-8103

BOSTON, MA – Analysis Group, one of the largest international economics consulting firms, is pleased to announce the promotions of Noam Kirson to Managing Principal and Jimmy Royer to Principal. 

“It is a pleasure to announce the promotions of Noam and Jimmy, who represent both the intellectual rigor and collaborative culture our firm is built on,” said Martha S. Samuelson, CEO and Chairman of Analysis Group. “Noam is valued by numerous health care industry participants for his contributions to health economics and outcomes research (HEOR) and strategy projects; including the design of outcomes-based contracts, analyses of clinical and real-world evidence, and development of advanced health economic models. Jimmy applies his expertise in data science and predictive modeling to help solve complex client challenges in a broad range of areas, including health care, finance, intellectual property, and antitrust. We look forward to their continued contributions to our clients' successes.”

New Managing Principal

Noam Kirson is an applied health economist with extensive experience in HEOR, strategy and market access, and complex litigation matters. He has worked closely with many different participants in the health care industry, including biopharmaceutical and device manufacturers, payers, government agencies, leading law firms, and academic experts. Dr. Kirson has managed numerous HEOR and strategy projects, including the design of outcomes-based contracts, analyses of pharmaceutical pricing issues, burden-of-illness studies, comparative-effectiveness research, cost-effectiveness evaluations, and budget impact assessments. He has presented this work at numerous academic conferences. Dr. Kirson also has experience presenting to health care industry regulators. For example, he supported a successful 510(k) pre-market submission to the US Food and Drug Administration (FDA) on behalf of a medical device manufacturer, including presentation of statistical analyses to an FDA advisory panel. His litigation case work has included evaluating antitrust matters in the health care sector, as well as assessing issues pertaining to the False Claims Act. Dr. Kirson is a member of the editorial board of Pharmacoeconomics Open and a member of the board of the ISPOR Boston Regional Chapter. He has published in peer-reviewed journals, including Health Affairs, Alzheimer's & Dementia, Diabetes Care, Critical Care Medicine, TheJournal of Clinical Psychiatry, and various pharmacoeconomic journals; and in legal and industry publications, such as Health Affairs Blog, STAT, and Law360.

New Principal

Jimmy Royer applies a broad range of quantitative tools to address client needs in data science, statistics, HEOR, finance, intellectual property, competition policy, and antitrust cases in the United States, Canada, and the EU. His recent work includes predicting the potential future onset of rare or undiagnosed conditions with machine learning models; predicting whether patents would be considered essential to technological standards if challenged in courts; valuing patents in the communications industry; evaluating damages related to product defects; analyzing investment guidelines in securities lending suits; addressing allegations of monopolization in major antitrust cases involving high technology firms; and supporting many academic experts on mutual fund market timing and excess fee cases. In addition, Dr. Royer has conducted extensive academic research and coauthored books and papers on topics such as using new AI advances in HEOR; predicting treatment resistance in tuberculosis, using machine learning algorithms in propensity score models; measuring the impact of ESO backdating on shareholders' wealth; analyzing mutual fund pricing; analyzing antitrust limit pricing; valuing private investments for hospitals in Canada; determining the impact of hypertension therapies on mortality; and comparing unemployment compensation in different countries.

To learn more about Analysis Group's capabilities, visit www.analysisgroup.com

# # #

About Analysis Group

Analysis Group is one of the largest economics consulting firms, with more than 900 professionals across 14 offices in North America, Europe, and Asia. Since 1981, we have provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune Global 500 companies, and government agencies worldwide. Our internal experts, together with our network of affiliated experts from academia, industry, and government, offer our clients exceptional breadth and depth of expertise.